☆ 4.7 Article

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma

Journal for ImmunoTherapy of Cancer (2015)

Get Full Text
Add to Collection

Journal

Journal for ImmunoTherapy of Cancer
Volume 3, Issue Suppl 2, Pages P157

Publisher

Springer Nature
DOI: 10.1186/2051-1426-3-s2-p157

Keywords

-

Categories

Immunology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.